To the Editor:
In their retrospective study1, Laskari and colleagues describe their experience of tapering mycophenolate mofetil (MMF) maintenance treatment in patients in renal remission after proliferative lupus nephritis. They compare the relapse rates of patients according to the timing of reduction of MMF. Among 18 patients with reduction of MMF therapy, 10 (56%) experienced a relapse, while only 6 of 26 patients (23%) with …
Address correspondence to Dr. Jourde-Chiche; E-mail: noemie.jourde{at}ap-hm.fr